panalo999 login
West Ham break Newcastle’s spell to lift pressure on Julen LopeteguiTAKING THE UNBEATEN PATH From left: Retired Supreme Court Associate Justice Antonio Carpio; IBP Human Rights Award recipients Edre Olalia, Kristian Jacob Lora and Antonio Azarcon; and fellow human rights lawyer Evalyn Ursua. Carpio and Ursua were on the panel of judges for the award. —Jane Bautista MANILA, Philippines — Brave clients, according to the late “people’s lawyer” Romeo Capulong who dedicated his life to defending human rights victims, deserve brave lawyers. And for the first time since its formation 51 years ago, the Integrated Bar of the Philippines (IBP) has cited three members of these “endangered breed” for their “exceptional contributions in the protection and advancement of human rights through the practice of law.” Named as recipients of the inaugural IBP Human Rights Awards were Edre Olalia for Luzon, Kristian Jacob Lora for the Visayas, and Antonio Azarcon for Mindanao, all members of the National Union of Peoples’ Lawyers (NUPL). READ: NUPL: IBP award affirms human rights lawyering, shields vs red-tagging “It is now the 51st year of the existence of IBP and it is only now that the IBP has engaged in this kind of activity to honor an endangered breed of lawyers who risk their lives and their limbs to defend human rights,” IBP president Antonio Pido said at the awarding ceremony held on Dec. 5 in Mandaluyong City. Olalia, the incumbent NUPL chair who has been advocating for over three decades for human rights, was the legal counsel of Flor Contemplacion, an experience he described as his “baptism of fire.” The Filipino domestic worker was executed in Singapore in 1995 after she was convicted in court for killing a fellow Filipino helper and a boy in her care four years earlier. While Contemplacion’s case ended in tragedy, it led Olalia into a career that has left an “indelible mark” on the human rights landscape in the country—from saving another overseas Filipino worker, Mary Jane Veloso, from being executed by the Indonesian government on drug charges, to securing the conviction of Army Gen. Jovito Palparan for the disappearance of University of the Philippines students and activists Sherlyn Cadapan and Karen Empeno. For Olalia, the IBP award was both a “vindication” and a “shield against the vicious Red-tagging” of his comrades-in-law. “This recognition is a sort of vindication against struggles with our families, colleagues, friends and classmates who cannot, do not and will not understand fully why we took this option,” he said in his acceptance speech. “In a nation where lawyers abound and battalions are added every single year, justice is inaccessible to many. We at NUPL took the unbeaten path, taking on causes and clients that many of our fellow lawyers do not, cannot or will not handle,” Olalia added. Lora, who has been practicing for just six years, is the youngest among the three awardees and represents the “new generation of people’s lawyers.” He is a member of NUPL-Cebu and a litigator of the Visayas Community Law Center, a law office that provides pro bono services to marginalized communities in the region in human rights and public interest litigation. His legal victories include securing the release of political prisoners like Liezyl Anne Gomez and defending those wrongfully accused under the Anti-Terrorism Act. He also worked for the acquittal of wrongfully accused individuals in the “Escalante 6” and “Himamaylan 3” cases. Lora said in his acceptance speech that he was still a law student when a group of protesting Kidapawan farmers was brutally dispersed by the police under the Aquino administration in 2016, and when thousands of drug suspects were killed under the Duterte administration. “The Duterte administration has diminished the value of human rights and embedded into the minds of our people that human rights are diametrically opposed to human lives. Evidently, we have a lot of work to do and, tonight, we begin,” Lora added. Azarcon, a seasoned lawyer who stood his ground during martial law, was later arrested in 1983 for his role in the Coalition of Organizations for the Restoration of Democracy (CORD), an alliance of groups opposed to the Marcos dictatorship. He was just 26 years old when he joined the Free Legal Assistance Group, offering pro bono legal assistance to victims of political persecution, extrajudicial killings and torture. “As a member of the Parliament of the Streets, I took on cases defending political prisoners and those subjected to arbitrary detention. My active role in Democracy CORD Mindanao led to my detention in 1983, but even then, I continued to advocate for justice through writing and other means,” Azarcon said. “These experiences only deepened my resolve and love for our country, driving me to fight for a future where every Filipino’s rights are respected and upheld,” he added. As NUPL assistant vice president for Mindanao, Azarcon vowed to remain committed to defending the rights of people in his region, especially against the threats of Red-tagging and extrajudicial killings. “While receiving this award is a moment of celebration, it is also a poignant reminder of the work that still lies ahead. The fight for human rights is ongoing, and we must remain vigilant and committed to addressing the challenges that persist,” he said. Subscribe to our daily newsletter By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy . This year’s IBP human rights awardees were chosen by a panel of judges composed of retired Supreme Court Senior Associate Justice Antonio Carpio, retired Court of Appeals Associate Justice Alfredo Ampuan, former University of the Philippines College of Law dean Pacifico Agabin, Adamson University College of Law dean Maria Anna Abad and human rights lawyer Evalyn Ursua.LINCOLN — There’s a cost to Nebraska football embracing its 34-year tradition of Black Friday games. A chance to reflect much, for one thing. Or celebrate, for another. NU on Saturday ended a 10-game losing streak to Wisconsin and a seven-season bowl drought in one fell swoop, but when the Huskers reconvened Monday, a short week of preparation for a nasty rival stared them right in the face. “We haven’t even had a team meeting since the game,” Nebraska coach Matt Rhule said at his weekly press conference. “We walked in today, 8 o’clock, and it’s Iowa special teams (prep). No time for ‘hey, great job.’ There’s no time for it.” Bad memories still linger in the Huskers’ minds, though. The Hawkeyes have won eight of the last nine in this series — six of those by one score, including last year, a 13-10 gut punch that kept Nebraska from making a bowl. If Iowa blew kisses at NU in 2019 on a game-winning field goal, they did something else in 2023. “Their players are waving at our guys — ‘hey, have a good Christmas!’ — that was painful,” Rhule said. “That was really painful. So I don’t doubt that our guys will be ready. But their guys will be ready. It really just comes down to football.” Win the turnover battle. Block and tackle well. Make plays when they’re available. Execute the way offensive coordinator Dana Holgorsen wants. To focus on those things — without the psychological pressure of a long December hanging over the program’s head — is a nice bonus to clinching the bowl before heading to Kinnick Stadium for a 6:30 p.m. game on NBC. The temps will be in the 20s; Nebraska, practicing outside most of the year, is prepared for that. Iowa’s offense, though fitted with a new coordinator, resembles a more effective version of the Hawkeyes’ recent attacks, with a blend of power and zone runs executed by running back Kaleb Johnson, second nationally in rush yards. Iowa ranks first in the Big Ten — and 13 th nationally — in rushing yards per game. “They’ve run some people off the field just by running the football down their throat,” Rhule said. So, Iowa is Iowa is Iowa. It was Iowa 10 years ago, when it lost 37-34 to Nebraska two days before the firing of Bo Pelini. It was Iowa two years ago on the day it lost to NU just as the school was finalizing a deal for Rhule. And at 7-4 overall — 5-3 in the Big Ten — this season, it is Iowa now. Nebraska, on the other hand, moved from a program with no bowl berths this decade to at least one this winter. It saw, in its win over Wisconsin, a work ethic rewarded, a process confirmed and a rare midseason offensive coordinator hire vindicated. “They know that they can do it, they know they’re capable of it,” Rhule said. “So let’s continue to do it. That’s the expectation now. What was once possible, now we know we can do it, so let’s do it.” Rhule anticipates Nebraska’s roster will be healthier after the flu ran through the team last week, and NU’s offense now manages playing time the way the Husker defensive coaches have — by who practices well during the week. That translated into backups who got more snaps against Wisconsin than other games this season — Emmett Johnson, Luke Lindenmeyer and Nate Boerkircher — and who stood more often on the sideline. That’s Holgorsen’s effect, to some degree, and it’s the new price of success. "Dana's brought a standard, offensively, that, I'm not going to say we didn't have before,” Rhule said, “but he has the experience to kind of follow through on it that will be good for us all to learn from.” The lessons learned in a game are the lessons learned in a season, Rhule said. The week is short, the prep is detailed and Iowa is Iowa. Who might Nebraska be? “We have to make sure the football’s right,” Rhule said. Get local news delivered to your inbox!
Trump isn't back in office but he's already pushing his agenda and negotiating with world leadersReport: Chargers expect WR Ladd McConkey, LB Khalil Mack to play vs. Ravens
ADELAIDE, Australia, and CAMBRIDGE, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, is reminding Shareholders to cast their vote in favor of the Scheme Implementation Agreement to re-domicile Bionomics from Australia to the U.S. "The re-domiciliation of Bionomics through the Scheme is key for our ability to execute our strategic vision and set the Company for success. I'd like to highlight that voting in favor of the Scheme was determined to be in the best interests of Bionomics Shareholders unanimously by the Board of Directors and an independent expert,” said Spyros Papapetropoulos, M.D., Ph.D., President and CEO of Bionomics. "I would like to thank each of the Shareholders that have already cast their vote and encourage those who haven't yet to do so well in advance of the Proxy cut-off date of 10:00 am New York time on December 3, 2024 for holders of American Depositary Shares and 8:30 am Sydney time on December 10, 2024 for holders of ordinary shares.” Bionomics Shareholders should carefully read the Scheme Booklet in its entirety before deciding on how to vote on the Scheme. The Scheme Meeting will be held at 8:30 am Sydney time on Thursday 12 December 2024 / 4:30 pm New York time on Wednesday 11 December 2024 via Bionomics' online meeting platform at https://meetnow.global/MCKR7AV . FOR FURTHER INFORMATION PLEASE CONTACT: Rajeev Chandra Company Secretary [email protected] Kevin Gardner [email protected] Chris Calabrese [email protected] Bionomics (NASDAQ: BNOX) is a clinical-stage biotechnology company developing novel, potential first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need. Bionomics is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder (SAD) and chronic treatment of post-traumatic stress disorder (PTSD). Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc. (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer's disease and other CNS conditions. Bionomics' pipeline also includes preclinical assets that target Kv3.1/3.2 and Nav1.7/1.8 ion channels being developed for CNS conditions of high unmet need. www.bionomics.com.au Forward-Looking Statements Bionomics cautions that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "may,” "could,” "will,” "would,” "should,” "expect,” "plan,” "anticipate,” "believe,” "estimate,” "intend,” "predict,” "seek,” "contemplate,” "potential,” "continue” or "project” or the negative of these terms or other comparable terminology are intended to identify forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to: the closing of each tranche of the Company's private placement financing, the achievement of certain milestones for the various tranches, the timely funding to the Company by each investor in the private placement, the timing, size and expectation of the closing of the private placement; and expectations regarding market conditions, the satisfaction of customary closing conditions related to the private placement and the anticipated use of proceeds therefrom; and the Company's expectation that its current cash, cash equivalents, and marketable securities will fund our operations into the third quarter of 2025. The inclusion of forward-looking statements should not be regarded as a representation by Bionomics that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company's business and other risks described in the Company's filings with the Securities and Exchange Commission (SEC), including, but not limited to, the Company's Annual Report on Form 20-F filed with the SEC, and its other reports. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Bionomics undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks, uncertainties and other factors is included in Bionomics' filings with the SEC, copies of which are available from the SEC's website (www.sec.gov) and on Bionomics' website (www.bionomics.com.au) under the heading "Investor Center.” All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995. Bionomics expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.North Macedonian political party demands ban on TikTok after at least 17 students injured
Francis' 23 lead NJIT over Navy 69-64
Fed's top expert on productivity sees case for optimismYou're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources , and more. Learn More Both Woodside Energy Group Ltd (ASX: WDS) and Commonwealth Bank of Australia (ASX: CBA) shares may appeal to investors who are looking for large, blue-chip shares. As the name suggests, CBA is a bank – it's the largest company in Australia. Woodside is a large energy business, focusing on LNG and oil, with projects around Australia, North America and Africa. When selecting an individual company for my portfolio, I want it to outperform the overall ASX share market. The company should either be more defensive, provide a stronger dividend yield, or have the potential for greater capital gains. While they're very different businesses, I'll compare both based on three factors in this article to decipher which stock is a better prospective buy for me. Dividend yield I'd guess that many Aussies who buy either of these businesses are doing so to take advantage of the passive income... Tristan Harrison
Economic Research: Global Economic Outlook Q1 2025: Buckle Up